Arthur A Levin Avidity Biosciences, Inc. (RNA) insider trading activity

Arthur A Levin is Director of Avidity Biosciences, Inc.. Currently has a direct ownership of 19,650 shares of RNA, which is worth approximately $668,886. The most recent transaction as insider was on Jun 10, 2025, when has been sold 6,692 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 19.7K

51.64% 3M change

32.5% 12M change

Total Value Held $668,886

ARTHUR A LEVIN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 10 2025	BUY Grant, award, or other acquisition	-	6,692 Added 25.4%	19,650 Common Stock
Jan 21 2025	SELL Open market or private sale	$53,539 $28.6 p/Share	1,872 Reduced 12.62%	12,958 Common Stock
Nov 19 2024	SELL Open market or private sale	$139,964 $42.12 p/Share	3,323 Reduced 18.31%	14,830 Common Stock
Nov 19 2024	BUY Exercise of conversion of derivative security	$4,120 $1.24 p/Share	3,323 Added 15.47%	18,153 Common Stock
Oct 21 2024	SELL Open market or private sale	$233,150 $46.63 p/Share	5,000 Reduced 25.21%	14,830 Common Stock
Oct 21 2024	BUY Exercise of conversion of derivative security	$6,200 $1.24 p/Share	5,000 Added 20.14%	19,830 Common Stock
Sep 19 2024	SELL Open market or private sale	$228,649 $45.73 p/Share	5,000 Reduced 25.21%	14,830 Common Stock
Sep 19 2024	BUY Exercise of conversion of derivative security	$6,200 $1.24 p/Share	5,000 Added 20.14%	19,830 Common Stock
Aug 19 2024	SELL Open market or private sale	$225,950 $45.19 p/Share	5,000 Reduced 25.21%	14,830 Common Stock
Aug 19 2024	BUY Exercise of conversion of derivative security	$6,200 $1.24 p/Share	5,000 Added 20.14%	19,830 Common Stock
Jul 19 2024	SELL Open market or private sale	$225,050 $45.01 p/Share	5,000 Reduced 25.21%	14,830 Common Stock
Jul 19 2024	BUY Exercise of conversion of derivative security	$6,200 $1.24 p/Share	5,000 Added 20.14%	19,830 Common Stock
Jun 20 2024	SELL Open market or private sale	$187,950 $37.59 p/Share	5,000 Reduced 25.21%	14,830 Common Stock
Jun 20 2024	BUY Exercise of conversion of derivative security	$6,200 $1.24 p/Share	5,000 Added 20.14%	19,830 Common Stock
May 20 2024	SELL Open market or private sale	$149,500 $29.9 p/Share	5,000 Reduced 25.21%	14,830 Common Stock
May 20 2024	BUY Exercise of conversion of derivative security	$6,200 $1.24 p/Share	5,000 Added 20.14%	19,830 Common Stock
Apr 19 2024	SELL Open market or private sale	$114,100 $22.82 p/Share	5,000 Reduced 25.21%	14,830 Common Stock
Apr 19 2024	BUY Exercise of conversion of derivative security	$6,200 $1.24 p/Share	5,000 Added 20.14%	19,830 Common Stock
Mar 19 2024	SELL Open market or private sale	$119,850 $23.97 p/Share	5,000 Reduced 25.21%	14,830 Common Stock
Mar 19 2024	BUY Exercise of conversion of derivative security	$6,200 $1.24 p/Share	5,000 Added 20.14%	19,830 Common Stock
Mar 12 2024	SELL Open market or private sale	$608,654 $22.02 p/Share	27,641 Reduced 65.08%	14,830 Common Stock
Mar 12 2024	BUY Exercise of conversion of derivative security	$31,000 $1.24 p/Share	25,000 Added 37.05%	42,471 Common Stock
Jan 22 2024	SELL Open market or private sale	$18,831 $10.13 p/Share	1,859 Reduced 9.62%	17,471 Common Stock
Mar 15 2023	SELL Open market or private sale	$2,201 $22.01 p/Share	100 Reduced 0.51%	19,330 Common Stock
Mar 15 2023	BUY Exercise of conversion of derivative security	$124 $1.24 p/Share	100 Added 0.51%	19,430 Common Stock

Also insider at

STOK

Stoke Therapeutics, Inc. Healthcare

AAL

Arthur A Levin

Director

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RNA shares.

Notify only if

Value

Insider Trading

Get notified when an Avidity Biosciences, Inc. insider buys or sells RNA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Avidity Biosciences, Inc.

Track Activities on RNA

Account